Centessa Pharmaceuticals plc
CNTA
Jodie situation report
Centessa Pharmaceuticals plc's current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 39 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.
- Company entered into a Transaction Agreement with Eli Lilly; the acquisition is expected to close in Q3 2026 subject to customary closing conditions, including regulatory and shareholder approvals.
Invalidation: The isolated read changes if CNTA's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind CNTA
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
GMABGenmab A/SpartnerNov 5, 2025 ▾
“Genmab License Agreement Background On February 14, 2025, the Company entered into a license agreement (the “License Agreement”) with Genmab A/S (“Genmab”) pursuant to which the Company granted to Genmab an exclusive worldwide license to leverage its propriet…”
LLYEli Lilly and CompanypartnerMay 5, 2026 ▾
“On March 31, 2026, the Company entered into a Transaction Agreement and plan of merger with Eli Lilly (the “Transaction Agreement”), pursuant to which the Company will be acquired in a transaction expected to close in the third quarter of 2026, subject to the…”
Depended on by
HRMYHarmony Biosciences Holdings, IcompetitorFeb 24, 2026 ▾
“Other potential future competitive products are currently in development, including Axsome Therapeutics’ AXS-12 (reboxetine) product candidate, Suven Life Sciences’ SUVN-G3031 H3 inverse agonist product candidate, NLS Pharmaceutics mazindol ER product candida…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
CNTA is currently a Follower in the organic co-movement group Biotechnology Innovations. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for CNTA; it is not active in the latest market snapshot.